Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This study was undertaken to determine whether use of the direct renin inhibitor aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease, cardiovascular disease, or both. METHODS: In a double-blind fashion, we randomly assigned 8561 patients to aliskiren (300 mg daily) or placebo as an adjunct to an angiotensin-converting-enzyme inhibitor or an angiotensin-receptor blocker. The primary end point was a composite of the time to cardiovascular death or a first occurrence of cardiac arrest with resuscitation; nonfatal myocardial infarction; nonfatal stroke; unplanned hospitalization for heart failure; end-stage renal disease, death attributable to kidney failure, or the need for renal-replacement therapy with no dialysis or transplantation available or initiated; or doubling of the baseline serum creatinine level. RESULTS: The trial was stopped prematurely after the second interim efficacy analysis. After a median follow-up of 32.9 months, the primary end point had occurred in 783 patients (18.3%) assigned to aliskiren as compared with 732 (17.1%) assigned to placebo (hazard ratio, 1.08; 95% confidence interval [CI], 0.98 to 1.20; P=0.12). Effects on secondary renal end points were similar. Systolic and diastolic blood pressures were lower with aliskiren (between-group differences, 1.3 and 0.6 mm Hg, respectively) and the mean reduction in the urinary albumin-to-creatinine ratio was greater (between-group difference, 14 percentage points; 95% CI, 11 to 17). The proportion of patients with hyperkalemia (serum potassium level, ≥6 mmol per liter) was significantly higher in the aliskiren group than in the placebo group (11.2% vs. 7.2%), as was the proportion with reported hypotension (12.1% vs. 8.3%) (P<0.001 for both comparisons). CONCLUSIONS: The addition of aliskiren to standard therapy with renin-angiotensin system blockade in patients with type 2 diabetes who are at high risk for cardiovascular and renal events is not supported by these data and may even be harmful. (Funded by Novartis; ALTITUDE ClinicalTrials.gov number, NCT00549757.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ACE inhibitors and ARBs should not be used together and should be used with caution with spironolactone to avoid hyperkalemia or AKI.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [259]
In the citing paper
“However, combination therapy was associated with a higher rate of hyperkalemia and AKI, 85,86”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [86]
In the citing paper
“Long-term outcome trials in patients with diabetes and CKD demonstrated no kidney or cardiovascular bene fi t of RAS blockade with combined therapy to block the RAS versus the single use of RAS inhibitors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [86]
In the citing paper
“Prior trials of dual renin–angiotensin system blockade have failed to show cardiovascular or kidney protection among patients with CKD and type 2 diabetes”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [25]
In the citing paper
“markedly lower than in trials of dual RAS blockade (4.8% with combination therapy with a direct renin inhibitor and an ACE inhibitor or ARB 20 and 9.2% with dual ACE inhibitor and ARB therapy 22 )”
From Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes (2020) · cites this paper as [20]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationHaffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Levey, A. S., Coresh, J., Greene, T., Stevens, L. A., Zhang, Y. (., Hendriksen, S., Kusek, J. W., & Van Lente, F. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-4-200608150-00004 · Cited by 5,725
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Self-citationTelmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
Self-citation
Research works printed but not linked: 1
- Pfeffer MA, 2010, Dial Cardiovasc Med, 15, 130
Cited by
Items 201–300 of 1,000
Recent Update of Renin-angiotensin-aldosterone System in the Pathogenesis of Hypertension
Moon, J.-Y. (2013) · Electrolytes & Blood Pressure · doi:10.5049/ebp.2013.11.2.41 · Cited by 81
“In order to investigate new targets for hypertension and kidney disease, further research on the function of the ACE-Ang-(1-7)-Mas receptor axis is required.”
BackgroundInfluentialGuía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Bénétos, A., Biffi, A., Boavida, J. M., Capodanno, D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.10.016 · Cited by 123
Inhibition of RAS in diabetic nephropathy
Campbell, K., & Yacoub, R. (2015) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s37893 · Cited by 81
“9 months and found that the combination therapy increased the risk of composite primary endpoint (ESRD, doubling of serum creatinine, renal death, cardiovascular death, cardiac arrest, heart failure, nonfatal myocardial infarction, or nonfatal stroke), along with hyperkalemia.(126) As many as 40% of subjects treated w…”
Pitt, B., & Bakris, G. L. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.04889 · Cited by 83
Lipid, blood pressure and kidney update 2013
Banach, M., Serban, C., Aronow, W. S., Rysz, J., Dragan, S., Lerma, E. V., Apetrii, M., & Covic, A. (2014) · International Urology and Nephrology · doi:10.1007/s11255-014-0657-6 · Cited by 73
“This has been supported by three trials, namely the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) [116], the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) [117] and the recently published the Veterans Affairs Nephropathy in Diabetes (VA-NEPHRON…”
InfluentialNagaraj, S. B., Pena, M. J., Ju, W., & Heerspink, H. J. L. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14178 · Cited by 93
Revisiting RAAS blockade in CKD with newer potassium-binding drugs
Georgianos, P. I., & Agarwal, R. (2017) · Kidney International · doi:10.1016/j.kint.2017.08.038 · Cited by 79
“5 mEq/l, older age, coexistence of diabetes or heart failure, and RAAS blockade.(6,8,9,12,13)”
Dietary sodium restriction: a neglected therapeutic opportunity in chronic kidney disease
Humalda, J. K., & Navis, G. J. (2014) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000073 · Cited by 84
Sarafidis, P. A., & Ruilope, L. M. (2013) · Kidney International · doi:10.1038/ki.2013.355 · Cited by 80
Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy
Johnson, S. A., & Spurney, R. F. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00266.2015 · Cited by 79
Qiao, Y.-C., Chen, Y.-L., Pan, Y.-H., Wei, L., Tian, F., Zhang, X., & Zhao, H. (2017) · Medicine · doi:10.1097/md.0000000000006583 · Cited by 78
New progress in drugs treatment of diabetic kidney disease
Wang, J., Xiang, H., Lu, Y., Wu, T., & Ji, G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111918 · Cited by 74
Nicholls, S. J., Bakris, G. L., Kastelein, J. J. P., Menon, V., Williams, B., Armbrecht, J., Brunel, P., Nicolaides, M., Hsu, A., Hu, B., et al. (2013) · JAMA · doi:10.1001/jama.2013.277169 · Cited by 74
Self-citationTargeting Cardiac Hypertrophy: Toward a Causal Heart Failure Therapy
Bisping, E. H., Wakula, P., Poteser, M., & Heinzel, F. R. (2014) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000126 · Cited by 82
“However, several trials have shown that the combination of RAAS inhibitors, despite synergistic, may increase the risk of unwanted side effects in some patients.(57,92) Third-generation MRA may reduce the risk of hyperkalemia and renal dysfunction and are advanced in clinical evaluation.”
BackgroundSouza, A. C. P., Bocharov, A. V., Baranova, I. N., Vishnyakova, T. G., Huang, Y. G., Wilkins, K. J., Hu, X., Street, J. M., Álvarez-Prats, A., Mullick, A. E., et al. (2016) · Kidney International · doi:10.1016/j.kint.2015.12.043 · Cited by 77
Bae, J. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0220 · Cited by 102
“Other therapies were linked to increased adverse events such as stroke [11], hyperkalemia [13,15], hypotension [13], acute kidney injury (AKI) [15], and major adverse cardiovascular events (MACE) [14].”
Role of Toll-like receptors in diabetic nephropathy
Mudaliar, H., Pollock, C. A., & Panchapakesan, U. (2014) · Clinical Science · doi:10.1042/cs20130267 · Cited by 75
Guidelines on the management of arterial hypertension and related comorbidities in Latin America
(2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001418 · Cited by 73
Cardiovascular Disease and Diabetic Kidney Disease
Maqbool, M., Cooper, M. E., & Jandeleit-Dahm, K. A. M. (2018) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.02.003 · Cited by 78
Schievink, B., Kröpelin, T., Mulder, S., Parving, H. ‐., Remuzzi, G., Dwyer, J., Vemer, P., de Zeeuw, D., & Lambers Heerspink, H. J. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12583 · Cited by 72
Self-citationFrom Proteinuria to Fibrosis: An Update on Pathophysiology and Treatment Options
Sharma, S., & Smyth, B. J. (2021) · Kidney & Blood Pressure Research · doi:10.1159/000516911 · Cited by 87
Ghazi, L., & Drawz, P. E. (2017) · F1000Research · doi:10.12688/f1000research.9692.1 · Cited by 81
Management of hypertension in chronic kidney disease
Townsend, R. R., & Taler, S. J. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.114 · Cited by 79
Leoncini, G., Viazzi, F. C., Cosmo, S. D., Russo, G. T., Fioretto, P., & Pontremoli, R. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00803-3 · Cited by 77
2013 ESH/ESC Guidelines for the management of arterial hypertension
(2013) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2013.07.015 · Cited by 75
Malachias, M. V. B., Jhund, P. S., Claggett, B. L., Wijkman, M. O., Bentley–Lewis, R., Chaturvedi, N., Desai, A. S., Haffner, S. M., Parving, H., PRESCOTT, M. F., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.017462 · Cited by 78
Self-citationPellicori, P., Ferreira, J. P., Mariottoni, B., Rocca, H. B., Ahmed, F. Z., Verdonschot, J. A. J., Collier, T. J., Cuthbert, J. J., Petutschnigg, J., Mujaj, B., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1716 · Cited by 75
Kanugula, A. K., Kaur, J., Batra, J., Ankireddypalli, A. R., & Velagapudi, R. (2023) · Cureus · doi:10.7759/cureus.40725 · Cited by 99
“Direct renin inhibitor: This has not improved renal or cardiovascular outcomes in patients with type 2 diabetes [197, 198].”
BackgroundDunbar, S. B., Reilly, C. M., GARY, R. A., Higgins, M. K., Culler, S. D., Butts, B., & Butler, J. (2015) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2015.05.012 · Cited by 75
Blood Pressure, Hypertension, RAAS Blockade, and Drug Therapy in Diabetic Kidney Disease
Yamout, H., Lazich, I., & Bakris, G. L. (2014) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2014.03.005 · Cited by 74
Gq signaling causes glomerular injury by activating TRPC6
Wang, L., Jirka, G., Rosenberg, P. B., Buckley, A. F., Gomez, J. A., Fields, T. A., Winn, M. P., & Spurney, R. F. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76767 · Cited by 68
“The dissociation between effects on proteinuria and renal injury is consistent with several clinical studies suggesting that treatments that inhibit proteinuria do not necessarily translate into reduced disease progression (11, 63).”
ResultD’Elia, L., Rossi, G., di Cola, M. S., Savino, I. G., Galletti, F., & Strazzullo, P. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09110914 · Cited by 68
Bavishi, C., Bangalore, S., & Messerli, F. H. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.10.002 · Cited by 76
Smad4 promotes diabetic nephropathy by modulating glycolysis and OXPHOS
Li, J., Sun, Y., Chen, W., Fan, J., Li, S., Qu, X., Chen, Q., Chen, R., Zhu, D., Zhang, J., et al. (2020) · EMBO Reports · doi:10.15252/embr.201948781 · Cited by 75
“Despite attempts at optimal blood glucose and blood pressure control, diabetic nephropathy (DN) develops in many patients [2,3], indicating that additional approaches are needed to halt the development and progression of DN.”
Hyperkalemia with RAAS inhibition: Mechanism, clinical significance, and management
Hundemer, G. L., & Sood, M. M. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105835 · Cited by 73
Prevalence and Management of Diabetic Nephropathy in Western Countries
Satirapoj, B., & Adler, S. G. (2015) · Kidney Diseases · doi:10.1159/000382028 · Cited by 80
Coca, S. G., Zabetian, A., Ferket, B. S., Zhou, J., Testani, J. M., Garg, A. X., & Parikh, C. R. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015060642 · Cited by 66
Developing Treatments for Chronic Kidney Disease in the 21st Century
Breyer, M. D., & Suszták, K. (2016) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2016.08.001 · Cited by 73
Phosphodiesterase Type 5 Inhibition Reduces Albuminuria in Subjects with Overt Diabetic Nephropathy
Scheele, W., Diamond, S., Gale, J., Clerin, V., Tamimi, N., Le, V., Walley, R., Grover-Páez, F., Perros-Huguet, C., Rolph, T., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015050473 · Cited by 65
Trensz, F., Bortolamiol, C., Kramberg, M., Wanner, D., Hadana, H., Rey, M., Strasser, D. S., Delahaye, S., Hess, P., Vezzali, E., et al. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.253864 · Cited by 65
“…mechanisms [e.g., bradykinin, angiotensin (1 – 7) accumulation, and angiotensin II type-2 receptor stimulation, and consequently nitric oxide release], and a depletion of the angio-tensinogen pool (Azizi and Ménard, 2004; Richer-Giudicelli et al., 2004; Parving et al., 2012; Fried et al., 2013).”
Glucose and Blood Pressure-Dependent Pathways–The Progression of Diabetic Kidney Disease
Patel, D. M., Bose, M., & Cooper, M. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062218 · Cited by 70
“The superiority of ARB compared to ACEis has been debated for a long time.”
BackgroundInfluentialCheng, Q., Boucher, B. J., & Leung, P. S. (2012) · Diabetologia · doi:10.1007/s00125-012-2801-0 · Cited by 69
“Indeed, the US Federal Drugs Authority recently advised that aliskiren should not be given to patients with renal dysfunction or diabetes, due to the risk of diabetic nephropathy [49, 50].”
BackgroundClinical Relevance of Local Renin Angiotensin Systems
Campbell, D. J. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00113 · Cited by 71
Donate‐Correa, J., Tagua, V. G., Ferri, C. M., Martín‐Núñez, E., Hernández-Carballo, C., Ureña, P., Ruiz‐Ortega, M., Ortíz, A., Fernández, C. M., & Navarro‐González, J. F. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030287 · Cited by 69
“However, this study was non-randomized, included only 14 participants, and used dual RAAS blockade, which has been related to important safety concerns [7,8,80].”
BackgroundOrtiz, A., Ferro, C. J., Balafa, O., Burnier, M., Ekart, R., Halimi, J.-M., Kreutz, R., Mark, P. B., Persu, A., Rossignol, P., et al. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab167 · Cited by 62
Eligibility for Renal Denervation: Experience at 11 European Expert Centers
Persu, A., Jin, Y., Baelen, M., Vink, E., Verloop, W. L., Schmidt, B., Blicher, M. K., Severino, F., Wuerzner, G., Taylor, A., et al. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.03194 · Cited by 62
Combination drug treatment in hypertension
Tsioufis, C. P., & Thomopoulos, C. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.09.011 · Cited by 65
Contribution of Predictive and Prognostic Biomarkers to Clinical Research on Chronic Kidney Disease
Provenzano, M., Rotundo, S., Chiodini, P., Gagliardi, I., Michael, A., Angotti, E., Borrelli, S., Serra, R., FOTI, D. P., Sarro, G. D., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165846 · Cited by 69
Hofherr, A., Williams, J. H., Gan, L., Söderberg, M. P., Hansen, P., & Woollard, K. J. (2022) · BMC Nephrology · doi:10.1186/s12882-022-02794-8 · Cited by 62
Faludi, A., Izar, M., Saraiva, J., Bianco, H. T., Chacra, A., Bertoluci, M., Moreira, R., Turatti, L., Bertolami, A., Sulzbach, M. L., et al. (2017) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20170188 · Cited by 107
The heart failure burden of type 2 diabetes mellitus—a review of pathophysiology and interventions
Ofstad, A. P., Atar, D., Gullestad, L., Langslet, G., & Johansen, O. E. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9685-0 · Cited by 59
“Side effects are also similar, except for increased risk of hyperkalemia with some agents blocking the RAAS system [3, 25, 76].”
BackgroundInfluentialImproving the efficacy of RAAS blockade in patients with chronic kidney disease
Heerspink, H. J. L., de Borst, M. H., Bakker, S. J. L., & Navis, G. J. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.281 · Cited by 59
Renal disease pathophysiology and treatment: contributions from the rat
Mullins, L. J., Conway, B. R., Menzies, R. I., Denby, L., & Mullins, J. J. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.027276 · Cited by 65
Bertoluci, M. C., Moreira, R. O., Faludi, A. Á., Izar, M. C. D. O., Schaan, B. D., Valério, C. M., Bertolami, M. C., Chacra, A. P. M., Malachias, M. V. B., Vencio, S. A. C., et al. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0251-z · Cited by 69
“In fact, aliskiren may even be harmful [152].”
BackgroundDiabetic nephropathy: newer therapeutic perspectives
Keri, K., Samji, N. S., & Blumenthal, S. S. (2018) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.1080/20009666.2018.1500423 · Cited by 70
EMPA-REG OUTCOME: The Nephrologist's Point of View
Wanner, C. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.007 · Cited by 57
Lipids, blood pressure and kidney update 2015
Banach, M., Aronow, W. S., Serban, M.-C., Rysz, J., Voroneanu, L., & Covic, A. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0169-0 · Cited by 56
“This has been supported by three trials, namely the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) [116], the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) [117] and the recently published the Veterans Affairs Nephropathy in Diabetes (VA-NEPHRON…”
MethodKidney Angiotensin in Cardiovascular Disease: Formation and Drug Targeting
Lin, H., Geurts, F., Hassler, L., BATLLE, D. C., Colafella, K. M. M., Denton, K. M., Zhuo, J. L., Li, X. C., Ramkumar, N., Koizumi, M., et al. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000236 · Cited by 60
Heerspink, H. J. L., Ninomiya, T., Persson, F., Brenner, B. M., Brunel, P., Chaturvedi, N., Desai, A. S., Haffner, S. M., Mcmurray, J. J. V., Solomon, S. D., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12600 · Cited by 57
“The study design and principal findings have been published previously [13,19].”
BackgroundSelf-citationClinical therapeutic strategies for early stage of diabetic kidney disease
Kitada, M. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i3.342 · Cited by 55
Renin-Angiotensin-Aldosterone System Blockade in Diabetic Nephropathy. Present Evidences
Maneiro, L. L., & Puente-García, A. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4111908 · Cited by 61
EMPA-REG OUTCOME: The Nephrologist's Point of View
Wanner, C. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.012 · Cited by 74
Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies
Valdivielso, J. M., Balafa, O. C., Ekart, R., Ferro, C. J., Mallamaci, F., Mark, P. B., Rossignol, P., Sarafidis, P. A., Vecchio, L. D., & Ortíz, A. (2021) · Drugs · doi:10.1007/s40265-021-01555-5 · Cited by 62
Nehme, A., & Zibara, K. (2017) · Hypertension Research · doi:10.1038/hr.2017.65 · Cited by 63
Renin-angiotensin-aldosterone system activation in long-standing type 1 diabetes
Lovshin, J. A., Boulet, G., Lytvyn, Y., Lovblom, L. E., Bjornstad, P., Farooqi, M. A., Lai, V., Cham, L., Tse, J., Orszag, A., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.96968 · Cited by 56
Kahlon, T. K., Carlisle, S. M., Mostacero, D. O., Williams, N., Trainor, P. J., & DeFilippis, A. P. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.06.005 · Cited by 62
Maggioni, A. P., Greene, S. J., Fonarow, G. C., Bohm, M., Zannad, F., Solomon, S. D., Lewis, E. F., Baschiera, F., Hua, T. A., Gimpelewicz, C. R., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht342 · Cited by 56
Self-citationPenno, G., Garofolo, M., & Prato, S. D. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.01.001 · Cited by 57
“Furthermore, over the past years, a number of high-profile clinical trials have reported failed treatments [8,9].”
BackgroundWei, X., Gao, P., Pu, Y., Li, Q., Yang, T., Zhang, H., Xiong, S., Cui, Y., Li, L., Ma, X., et al. (2017) · Clinical Science · doi:10.1042/cs20160780 · Cited by 55
Effect of glucose-lowering therapies on heart failure
Nassif, M. E., & Kosiborod, M. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.211 · Cited by 55
Barrera‐Chimal, J., Kolkhof, P., Lima‐Posada, I., Alexandre, J., Rossignol, P., & Jaisser, F. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.2002844 · Cited by 54
Feng, Y., Huang, R., Kavanagh, J., Li, L., Zeng, X., Li, Y., & Fu, P. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-00321-5 · Cited by 53
Blood pressure control in hypertension. Pros and cons of available treatment strategies
Mancia, G., Rea, F., Cuspidi, C., Grassi, G. M., & Corrao, G. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000001181 · Cited by 62
“Guidelines also mention that other combinations can be used, (for example, an ACE-inhibitor and a b-blocker in hypertensive patients with coronary disease) whereas discouraging the concomitant administration of an ACE inhibitor and an angiotensin receptor antagonist because of the inconveniences exhibited in outcome t…”
Neurohormonal Blockade in Heart Failure
von Lueder, T. G., Kotecha, D., Atar, D., & Hopper, I. (2017) · Cardiac failure review · doi:10.15420/cfr.2016:22:2 · Cited by 56
Antioxidant for treatment of diabetic nephropathy: A systematic review and meta-analysis
Kandhare, A. D., Mukherjee-Kandhare, A. A., & Bodhankar, S. L. (2017) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2017.10.031 · Cited by 52
New medical therapies for heart failure
von Lueder, T. G., & Krum, H. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.137 · Cited by 55
SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives
Piperidou, A., Loutradis, C., & Sarafidis, P. A. (2020) · Journal of Human Hypertension · doi:10.1038/s41371-020-00393-4 · Cited by 51
Contrast-Associated Acute Kidney Injury
Mirizzi, A. M., Munafò, A. R., & Crimi, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11082167 · Cited by 53
“In a study by Chong et al., CA-AKI occurred in 12% of patients undergoing PCI during ST-elevation myocardial infarction (STEMI), 9.2% of patients with unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI), and 4.5% of patients undergoing elective PCI (p = 0.0005) [15].”
BackgroundInfluentialRenin–Angiotensin–Aldosterone System: From History to Practice of a Secular Topic
Ksiazek, S. H., Hu, L., Andò, S., Pirklbauer, M., Säemann, M. D., Ruotolo, C., Zaza, G., Manna, G. L., Nicola, L. D., Mayer, G. J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25074035 · Cited by 66
“The combination of direct renin inhibition with aliskiren and standard of care with ACEi/ARB was analyzed by the ALTITUDE trial; however, the trial was terminated prematurely due to a higher occurrence of primary end-points (composite of the time to CV and renal events) in the aliskiren group [33].”
BackgroundMethodGale, J. D., Gilbert, S., Blumenthal, S., Elliott, T., Pergola, P. E., Goteti, K., Scheele, W., & Perros-Huguet, C. (2018) · Kidney International Reports · doi:10.1016/j.ekir.2018.07.010 · Cited by 50
Sánchez, J. J. G., Thompson, J. C., Scott, D. A., Evans, R., Rao, N., Sörstadius, E., James, G., NOLAN, S. T., Wittbrodt, E. T., Sultan, A. A., et al. (2021) · Advances in Therapy · doi:10.1007/s12325-021-02006-z · Cited by 64
“8%) were stopped early due to low recruitment or low event rates (n = 2) [47, 100], safety concerns (n = 5) [53, 57, 73, 74, 115], negative results reported in a sister trial (n = 1) [72], other reasons (n = 1) [61], or for reasons not provided (n = 1) [113].”
BackgroundSlowing progression of chronic kidney disease
Drawz, P. E., & Rosenberg, M. E. (2013) · Kidney International Supplements · doi:10.1038/kisup.2013.80 · Cited by 65
“The ALTITUDE trial studied the effects of adding the renin inhibitor aliskiren to ACEI or ARB therapy.(17) This study was terminated early secondary to adverse outcomes including hyperkalemia, hypotension, and stroke.”
Lullo, L. D., Lavalle, C., Scatena, A., Mariani, M. V., Ronco, C., & Bellasi, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12123992 · Cited by 55
“In conclusion, although there are no experimental data from specific RCTs and previous RCTs evaluating combination therapies acting on the blockade of RAS pathway resulted in safety concerns [82,110,111], the preclinical data and results of several sub-analyses suggest that the combination of finerenone with SGLT2i is…”
ResultComorbidity of patients with noncommunicable diseases in general practice. Eurasian guidelines
Drapkina, O. M., Васильевна, К. А., Калинина, А. М., Avdeev, S. N., Викторович, А. М., Алексеева, Л. И., Almazova, I. I., Andreenko, Е. Y., Antipushina, D. N., Balanova, Y. А., et al. (2024) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2024-3996 · Cited by 65
Mild hypertension in people at low risk
Martin, S. A., Boucher, M., Wright, J. M., & Saini, V. (2014) · BMJ · doi:10.1136/bmj.g5432 · Cited by 56
Heerspink, H. J. L., Persson, F., Brenner, B. M., Chaturvedi, N., Brunel, P., McMurray, J. J. V., Desai, A. S., Solomon, S. D., Pfeffer, M. A., PARVING, H.-H. D., et al. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00469-6 · Cited by 52
Self-citationKalkman, D. N., Brouwer, T. F., Vehmeijer, J. T., Berger, W. R., Knops, R. E., de Winter, R. J., Peters, R. J., & van den Born, B.-J. H. (2017) · Circulation · doi:10.1161/circulationaha.117.030342 · Cited by 49
Owen, J., & Reisin, E. (2015) · Current Hypertension Reports · doi:10.1007/s11906-015-0558-9 · Cited by 54
Esteras, R., Pérez-Gómez, M. V., Rodríguez-Osorio, L., Ortíz, A., & Fernández‐Fernández, B. (2015) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098615589905 · Cited by 51
“2008], Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints, ALTITUDE [Parving et al.”
MethodInfluentialNew Therapies for the Treatment of Renal Fibrosis
Liu, F., & Zhuang, S. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-8871-2_31 · Cited by 51
Sarafidis, P. A., Iatridi, F., Ferro, C. J., Alexandrou, M. E., Fernández‐Fernández, B., Kanbay, M., Mallamaci, F., Nistor, I., Rossignol, P., Wanner, C., et al. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad139 · Cited by 48
“However, such multifactorial interventions have been recommended for decades with implementation rates that are not optimal, while several disappointing RCTs have been performed in patients with CKD and T2D, with agents such as bardoxolone [ 147 ], aliskiren [ 11 , 148 ] and darbe-poetin [ 149 ].”
BackgroundResultInfluentialHypertension and chronic kidney disease
Gargiulo, R., Suhail, F., & Lerma, E. V. (2015) · Disease-a-Month · doi:10.1016/j.disamonth.2015.07.003 · Cited by 55
Heerspink, H. J. L., Gao, P., de Zeeuw, D., Clase, C. M., Dagenais, G. R., Sleight, P., Lonn, E., Teo, K. K., Yusuf, S., & Mann, J. F. E. (2013) · European Journal of Preventive Cardiology · doi:10.1177/2047487313510678 · Cited by 51
“The rise in serum potassium is not only observed with combined ACEI and ARB therapy, as we report here, but has also been observed during combination therapy with direct renin inhibitors.(9,14,15) In the ALTITUDE trial, 907 (21.”
BackgroundResultRuiz‐Hurtado, G., Condezo‐Hoyos, L., Pulido-Olmo, H., Aránguez, I., González, M. C., Arribas, S. M., Cerezo, C., Segura, J., Praga, M., Fernández‐Alfonso, M. S., et al. (2014) · Journal of Hypertension · doi:10.1097/hjh.0000000000000292 · Cited by 51
Epidemiology of left ventricular hypertrophy in hypertension: implications for the clinic
Cramariuc, D., & Gerdts, E. (2016) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2016.1186542 · Cited by 54
“However, results from the Aliskiren Trial in Type 2 Diabetes Using CardioRenal Endpoints study demonstrated that aliskiren did not improve outcome in such patients, and dual RAS inhibition with combined aliskiren and ARB was less safe with increased adverse events, renal complications, hyperkalemia, and hypotension [1…”
ResultMineralocorticoid Antagonism and Diabetic Kidney Disease
Lytvyn, Y., Godoy, L. C., Scholtes, R. A., van Raalte, D. H., & Cherney, D. Z. I. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1123-8 · Cited by 52
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Rosei, E., Azizi, M., Burnier, M., Clement, D., Coca, A., de Simone, G., Dominiczak, A. F., et al. (2019) · Revista Española de Cardiología · doi:10.1016/j.recesp.2018.12.005 · Cited by 67
Management of diabetic renal disease.
Eboh, C., & Chowdhury, T. A. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.06.25 · Cited by 47
“Both ACEI and ARBs reduced progression from micro- to macroalbuminuria, and ARBs reduced risk of ESRF and doubling of creatinine more than placebo.”
BackgroundFernández‐Fernández, B., Fernández-Prado, R., Górriz, J. L., Martínez‐Castelao, A., Navarro‐González, J. F., Porrini, E., Soler, M. J., & Ortíz, A. (2019) · Clinical Kidney Journal · doi:10.1093/ckj/sfz070 · Cited by 48
Morales, E., Cravedi, P., & Manrique, J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.653634 · Cited by 56
“Nevertheless, side effects limit their use, particularly associated to diuretics (39), dual blockade of RAAS [“Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial,” ONTARGET (40), or “Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints,” ALTITUDE] (41, 42), or neprylisin inhibit…”
Background
Metadata
- Authors
- Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., Richard, A., Xiang, Z., Brunel, P., & Pfeffer, M. A.
- Affiliations
- University of Copenhagen (DK)
- Brigham and Women's Hospital (US)
- The University of Texas at San Antonio Health Science Center (US)
- Imperial College London (GB)
- Steno Diabetes Centers (DK)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-12-06
- Volume
- 367
- Issue
- 23
- Pages
- 2204-2213
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138862624
- Cited by
- 1,319
- References
- 40
- Citations by year
- 2026: 30 · 2025: 41 · 2024: 52 · 2023: 68 · 2022: 61 · 2021: 75 · 2020: 73 · 2019: 96 · 2018: 93 · 2017: 124 · 2016: 117 · 2015: 151 · 2014: 166 · 2013: 159 · 2012: 11
- FWCI
- 100.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Research Bank (Australian Catholic University) (submittedVersion)
- Institutional Research Information System (University of Udine) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- IRIS (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- UnissResearch (Università degli Studi di Sassari) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Open Access CRIS of the University of Bern
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- aliskiren, type 2 diabetes, chronic kidney disease, renin-angiotensin system blockade, ACE inhibitors, angiotensin receptor blockers, cardiovascular events, end-stage renal disease, hyperkalemia, hypotension, albumin-creatinine ratio, blood pressure reduction, cardiorenal outcomes
- MeSH terms
- Renin Inhibitors, Aged, Amides, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Fumarates, Humans, Hyperkalemia, Hypokalemia, Kidney Diseases, Male, Middle Aged, Patient Dropouts, Treatment Failure, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.